Glioblastoma Foundation to Support Development of Osmertinib

Osmertinib is an FDA approved EGFR kinase inhibitor showing promise against EGFR vIII positive GBM.  It is effective in a subset of patients with the EGFR vIII genotype.

Glioblastoma Foundation is proud to support clinical development of this drug for GBM patients with this genetic profile.

We encourage all patients to get their tumor genotype tested.

To show your support or to find out how you can get involved please contact us.


The current standard of care for glioblastoma consisting of radiation and chemotherapy is ineffective.

Help Us Transform Glioblastoma Therapy